Referred to the House Committee on Energy and Commerce.
The bill amends the Federal Food, Drug, and Cosmetic Act to require labels on human drugs to disclose any ingredient that is a major food allergen or derived from a gluten-containing grain, and to identify each such ingredient and the type of gluten-containing grain. The labeling requirement becomes effective on a date set by HHS or two years after enactment, whichever is earlier.
Progressives emphasize patient safety and transparency benefits.
Relative to its intended legislative type, this bill is a direct substantive amendment to the FD&C Act that clearly imposes a new labeling obligation and fits structurally into existing misbranding enforcement authorities, but it omits several definitional, operational, and resourcing details that would aid consistent implementation.
The bill amends the Federal Food, Drug, and Cosmetic Act to require labels on human drugs to disclose any ingredient that is a major food allergen or derived from a gluten-containing grain, and to identify each such ingredient and the type of gluten-containing grain.
The labeling requirement becomes effective on a date set by HHS or two years after enactment, whichever is earlier.
A modest, safety-oriented labeling requirement with no direct spending; often acceptable legislative terrain, but regulatory ambiguity and industry resistance reduce certainty.
Relative to its intended legislative type, this bill is a direct substantive amendment to the FD&C Act that clearly imposes a new labeling obligation and fits structurally into existing misbranding enforcement authorities, but it omits several definitional, operational, and resourcing details that would aid consistent implementation.
Progressives emphasize patient safety and transparency benefits.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize patient safety and transparency benefits.
Likely supportive: the bill increases transparency and protects people with food allergies or gluten sensitivities.
It aligns drug labeling with consumer-safety norms and could reduce allergic adverse events.
Generally favorable but pragmatic: supports patient safety and transparency while worrying about regulatory clarity, implementation timelines, and reasonable cost control.
Would seek technical guidance and phased implementation.
Skeptical: while sympathetic to consumer safety, the persona worries this imposes additional federal regulatory burdens and costs on pharmaceutical manufacturers and could harm innovation.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
A modest, safety-oriented labeling requirement with no direct spending; often acceptable legislative terrain, but regulatory ambiguity and industry resistance reduce certainty.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize patient safety and transparency benefits.
A modest, safety-oriented labeling requirement with no direct spending; often acceptable legislative terrain, but regulatory ambiguity and…
Relative to its intended legislative type, this bill is a direct substantive amendment to the FD&C Act that clearly imposes a new labeling obligation and fits structurally into existing misbranding enforcement authoriti…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.